Antibody directed enzyme prodrug therapy (ADEPT): A review of the experimental and clinical considerations

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 605-613

  Syrigos, Konstantinos N ^a,c   Epenetos, Agamemnon A ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Antisoma plc   (United Kingdom)

^c Department of Medical Oncology ^*  (Greece)

Author keywords

Cytotoxic therapy; Monoclonal antibodies; Prodrug

Indexed keywords

ENZYME; MONOCLONAL ANTIBODY; PRODRUG;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; CANCER CHEMOTHERAPY; DRUG ACTIVITY; DRUG CYTOTOXICITY; HUMAN; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ALKALINE PHOSPHATASE; ANIMALS; ANTIBODIES, MONOCLONAL; BETA-GLUCOSIDASE; CARBOXYPEPTIDASES; ENZYMES; HUMANS; NEOPLASMS; NITROREDUCTASES; PRODRUGS;

EID: 0032897384     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined speaficity. Nature 256: 495-7, 1975.
2. Kohler G, Milstein C: Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 6: 511-9, 1976.
3. Whisson ME, Connors TA: Cure of mice bearing advanced plasma cell tumours with aniline mustard. Nature 206: 689-91, 1965.
4. Connors TA, Farmer PB, Foster AB, Gilsenan AM, Jarman M, Tisdale MJ: Metabolism of aniline mustard (N,N-di-(2-chloroethyl) aniline). Biochem Pharmacol 22: 1971-80, 1973.
5. Connors TA, Foster AB, Gilsenan AM, Jarman M, Tisdale MJ: Chemical trapping of a reactive metabolite. The metabolism of the AZO-mustard 2'-carboxy-4-di-(2-chloroethyl)amino-2-methylazobenzene. Biochem Pharmacol 21: 1309-16, 1972.
6. Wilman DE: Prodrugs in cancer chemotherapy. BiQchem Soc Trans 14: 375-82, 1986.
7. Newlands ES, Blackledge G, Slack JA, Goddard C, Brindley CJ, Holden L, Stevens MF: Phase 1 clinical trial of mitozolomide. Cancer Treat Rep 69: 801-5, 1985.
8. Connors TA, Cumber AJ, Ross WC, Clarke SA, Mitchley BC: Regression of human lung tumor xenografts induced by water-soluble analogs of hexamethylmelamine. Cancer Treat Rep 61: 927-8, 1977.
9. Philpott GW, Bower RJ, Parker CW: Selective iodination and cytotoxicity of tumor cells with an antibody-enzyme conjugate. Surgery 74: 51-8, 1973.
10. Philpott GW, Shearer WT, Bower RJ, Parker CW: Selective cytotoxicity of hapten-substituted cells with an antibody-enzyme conjugate. J Immunol 111: 921-9, 1973.
11. Bagshawe KD: Antibody directed enzymes revive anti-cancer prodrugs concept. Br J Cancer 56: 531-2, 1987.
12. Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG, Sherwood RF: A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 58: 700-3, 1988.
13. Senter PD Saulnier MG Schreiber GJ Hirschberg DL Brown JP Hellström I Hellström KE: Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 85: 4842-6, 1988.
14. Senter PD, Schreiber GJ, Hirschberg DL, Ashe SA, Hellström KE, Hellström I: Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res 49: 5789-92, 1989.
15. Begent RH: Recent advances in tumour imaging. Use of radiolabelled antitumour antibodies. Biochim Biophys Acta 780: 151-66, 1985.
16. Haenseler E, Esswein A, Vitols KS, Montejano Y, Mueller BM, Reisfeld RA, Huennekens FM: Activation of methotrexate-alpha-alanine by carboxypeptidase A-monoclonal antibody conjugate. Biochemistry 31: 891-7, 1992.
17. Mason DW, Williams AF: The kinetics of antibody binding to membrane antigens in solution and at the cell surface. Biochem J 187: 1-20, 1980.
18. Gordon J, Anderson VA, Robinson DS, Stevenson GT. The influence of antigen density and a comparison of IgG and IgM antibodies in the anti-complementary modulation of lymphocytic surface immunoglobulin. Scand J Immunol 15: 169-77, 1982.
19. 131I antibody to human chorionic gonadotrophin: preliminary communication. J R Soc Med 73: 624-30, 1980.
20. Bagshawe KD: Towards generating cytotoxic agents at cancer sites. Br J Cancer 60: 275-81, 1989.
21. Primus FJ, Kuhns WJ, Goldenberg DM: Immunological heterogeneity of carcinoembryonic antigen: immunohistochemical detection of carcinoembryonic antigen determinants in colonic tumors with monoclonal antibodies. Cancer Res 43: 693-701, 1983.
22. Begent RH, Ledermann JA, Green AJ, Bagshawe KD, Riggs SJ, Searle F, Keep PA, Adam T, Dale RG, Glaser MG: Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Br J Cancer 60: 406-12, 1989.
23. Boxer GM, Begent RH, Kelly AM, Southall PJ, Blair SB, Theodorou NA, Dawson PM, Ledermann JA: Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma-implications for radioimmunotherapy. Br J Cancer 65: 825-31, 1992.
24. Tagliabue E, Porro G, Barbanti P, Della Torre G, Menard S, Rilke F: Improvement of tumor cell detection using a pool of monoclonal antibodies. Hybridoma 5: 107-15, 1986.
25. Chan SY, Evan GI, Ritson A, Watson J, Wraight P, Sikora K: Localisation of lung cancer by a radiolabelled monoclonal antibody against the c-myc oncogene product. Br J Cancer 54: 761-9, 1986.
26. Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C, Shalaby R, Kotts C, Wood WI: Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 92: 1327-31, 1995.
27. 111In-labeled human tumor reactive monoclonal IgM AC6C3-2B12. Cancer Res 55: 5736-42, 1995.
28. Cobb LM, Humphreys JA, Harrison A: The diffusion of a tumour-specific monoclonal antibody in lymphoma infiltrated spleen. Br J Cancer 55: 53-5, 1987.
29. Moshakis V, McIlhinney RA, Neville AM: Cellular distribution of monoclonal antibody in human tumours after i.v. administration. Br J Cancer 44: 663-9, 1981.
30. Moshakis V, McIlhinney RA, Raghavan D, Neville AM: Localization of human tumour xenografts after i.v. administration of radiolabeled monoclonal antibodies. Br J Cancer 44: 91-9, 1981.
31. Boucher Y, Baxter LT, Jain RK: Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 50: 4478-84, 1990.
32. Baldini N: Multidrug resistance-a multiplex phenomenon. Nature Med 3: 378-80, 1997.
33. Bagshawe KD, Sharma SK, Springer CJ, Rogers GT: Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects. Ann Oncol 5: 879-91, 1994.
34. Sherwood RF, Melton RG, Alwan SM, Hughes P: Purification and propetries of carboxypeptidase G2 from Pseudomonas sp strain RS-16. Use of a novel triazine dye affinity method. Europ J Biochem 148: 447-53, 1985.
35. Minton NP, Atkinson T, Bruton CJ, Sherwood RF: The complete nucleotide sequence of the Pseudomonas gene coding for carboxypeptidase G2. Gene 31: 31-8, 1984.
36. Springer CJ, Bagshawe KD, Sharma SK, Searle F, Boden JA, Antoniw P, Burke PJ, Rogers GT, Sherwood RF, Melton RG: Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur J Cancer 27: 1361-6, 1991.
37. Searle F, Partridge CS, Kardana A, Green AJ, Buckley RG, Begent RH, Rawlins-GA: Preparation and properties of mouse monoclonal antibody (W14A) to human chorionic gonadotropin. Int J Cancer 33: 429-34, 1984.
38. Searle F, Bier C, Buckley RG, Newman S, Pedley RB, Bagshawe KD, Melton RG, Alwan SM, Sherwood RF: The potential of carboxypeptidase G2-antibody conjugates as anti-tumour agents. I. Preparation of antihuman chorionic gonadotrophin-carboxypeptidase G2 and cytotoxicity of the conjugate against JAR choriocarcinoma cells in vitro. Br J Cancer 53: 377-84, 1986.
39. Melton RG, Searle F, Sherwood RF, Bagshawe KD, Boden JA: The potential of carboxypeptidase G2: antibody conjugates as antitumour agents, in vivo localisation and clearance properties in a choriocarcinoma model. Br J Cancer 61: 420-4, 1990.
40. Antoniw P, Springer CJ, Bagshawe KD, Searle F, Melton RG, Rogers GT, Burke PJ, Sherwood RF: Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice. Br J Cancer 62: 909-14, 1990.
41. Bagshawe KD, Sharma SK, Springer CJ, Antoniw P: Antibody directed enzyme prodrug therapy: a pilot-scale clinical trial. Tumour Target 1: 17-9, 1995.
42. Kuefner U, Lohrmann U, Montejano YD, Vitols KS, Huennekens FM: Carboxypeptidase-mediated release of methotrexate from methotrexate alpha-peptides. Biochemistry 28: 2288-97, 1989.
43. Senter PD, Su PC, Katsuragi T, Sakai T, Cosand WL, Hellstrom I, Hellstrom KE: Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconjug Chem 2: 447-51, 1991.
44. Wallace PM, Senter PD: In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate. Bioconjug Chem 2: 349-52, 1991.
45. Wallace PM, Senter PD: Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Methods Find Exp Clin Pharmacol 16: 505-12, 1994.
46. Kerr DE, Senter PD, Burnett WV, Hirschberg DL, Hellstrom I, Hellstrom KE: Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol Immunother 31: 202-6, 1990.
47. Bignami GS, Senter PD, Grothaus PG, Fischer KJ, Humphreys T, Wallace PM: N-(4'-hydroxyphenylacetyl)palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate. Cancer Res 52: 5759-64, 1992.
48. Vrudhula VM, Senter PD, Fischer KJ, Wallace PM: Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate. J Med Chem 36: 919-23, 1993.
49. Wallace PM, MacMaster JF, Smith VF, Kerr DE, Senter PD, Cosand WL: Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res 54: 2719-23, 1994.
50. Senter PD: Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. FASEB J 4: 188-93, 1990.
51. Senter PD, Wallace PM, Svensson HP, Kerr DE, Hellstrom I Hellstrom KE: Activation of prodrugs by antibody-enzyme conjugates. Adv Exp Med Biol 303: 97-105, 1991.
52. Galleni M, Lindberg F, Normark S, Cole S, Honore N, Joris B, Frere JM: Sequence and comparative analysis of three Enterobacter cloacae ampC beta-lactamase genes and their products. Biochem J 250: 753-60, 1988.
53. Vrudhula VM, Svensson HP, Kennedy KA, Senter PD, Wallace PM: Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-beta-lactamase conjugates. Bioconjug Chem 4: 334-40, 1993.
54. Svensson HP, Vrudhula VM, Emswiler JE, MacMaster JF, Cosand WL, Senter PD, Wallace PM. in vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates. Cancer Res 55: 2357-65, 1995.
55. Svensson HP, Wallace PM, Senter PD: Synthesis and characterization of monoclonal antibody-beta-lactamase conjugates. Bioconjug Chem 5: 262-7, 1994.
56. Meyer DL, Jungheim LN, Mikolajczyk SD, Shepherd TA, Starling JJ, Ahlem CN: Preparation and characterization of a beta-lactamase-Fab conjugate for the site-specific activation of oncolytic agents. Bioconjug Chem 3: 42-8, 1992.
57. Haisma HJ, Boven E, van Muijen M, de Jong J, van der Vijgh WJ, Pinedo HM: A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br J Cancer 66: 474-8, 1992.
58. Haisma HJ, van Muijen M, Pinedo HM, Boven E: Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-beta-glucuronidase conjugate in the specific treatment of cancer. Cell Biophys 24-25: 185-92, 1994.
59. Roffler SR, Wang SM, Chern JW, Yeh MY, Tung E: Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem Pharmacol 42: 2062-5, 1991.
60. Wang SM, Chern JW, Yeh MY, Ng JC, Tung E, Roffler SR: Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res 52: 4484-91, 1992.
61. Bosslet K, Czech J, Lorenz P, Sedlacek HH, Schuermann M, Seemann G: Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. Br J Cancer 65: 234-8, 1992.
62. Bosslet K, Czech J, Hoffmann D, Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res 54: 2151-9, 1994.
63. Bosslet K, Czech J, Seemann G, Monneret C, Hoffmann D: Fusion protein mediated prodrug activation (FMPA) in vivo. Cell Biophys 24-25: 51-63, 1994.
64. Knox RJ, Boland MP, Friedlos F, Coles B, Southan C, Roberts JJ: The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem Pharmacol 37: 4671-7, 1988.
65. Knox RJ, Friedlos F, Boland MP: The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metastasis Rev 12: 195-212, 1993.
66. Anlezark GM, Melton RG, Sherwood RF, Wilson WR, Denny WA, Palmer BD, Knox RJ, Friedlos F, Williams A: Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem Pharmacol 50: 609-18, 1995.
67. Weinreb NJ, Brady RO, Tappel AL: The lysosomal localization of sphingolipid hydrolases. Biochim Biophys Acta 159: 141-6, 1968.
68. Mueller OT, Rosenberg A: beta-Glucoside hydrolase activity of normal and glucosylceramidotic cultured human skin fibroblasts. J Biol Chem 252: 825-9, 1977.
69. Mueller OT, Rosenberg A: Activation of membrane-bound glucosylceramide: beta-glucosidase in fibroblasts cultured from 33 normal and glucosylceramidotic human skin. J Biol Chem 254: 3521-5, 1979.
70. Moertel CG, Fleming TR, Rubin J, Kvols LK, Sarna G, Koch R, Currie VE, Young CW, Jones SE, Davignon JP: A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 306: 201-6, 1982.
71. KN Syrigos, G Rowlinson-Busza, AA Epenetos. in vitro cytotoxicity following specific activation of amygdalin by B glucosidase conjugated to a bladder cancer-associated monoclonal antibody. Int J Cancer (in press).
72. KN Syrigos, M Khawaja, T Krausz, G Williams, AA Epenetos-Intravesical Administration of Radiolabelled Tumour Associated Monoclonal Antibody in Bladder Cancer. Acta Oncol (in press).
73. Sharma SK, Bagshawe KD, Burke PJ, Boden JA, Rogers GT, Springer CJ, Melton RG, Sherwood RF: Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy. Cancer 73: 1114-20, 1994.
74. Sharma SK, Bagshawe KD, Springer CJ, Burke PJ, Rogers GT, Boden JA: Antibody directed enzyme prodrug therapy (ADEPT): a three phase system. Dis Marker 9: 225-31, 1991.
75. Mattes MJ: Biodistribution of antibodies after intraperitoneal and intravenous injection and effect of carbohydrate modification. J Natl Cancer Inst 79: 855-863, 1987.
76. Shokat KM, Leumann CJ, Sugasawara R, Schultz PG: A new strategy for the generation of catalytic antibodies. Nature 338: 269-71, 1989.
77. Wilkinson I, Jackson CJ, Lang GM, Holford-Strevens V, Schon AH: Tolerance induction in mice by conjugates of monoclonal immunoglobulins and monomethoxypolyethylene glycol. Transfer of tolerance by T cells and by T cell extracts. J Immunol 139: 326-31, 1987.